{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:22:51Z","timestamp":1773260571592,"version":"3.50.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008463","name":"Universitas Airlangga","doi-asserted-by":"publisher","award":["166\/UN3.LPPM\/PT.01.09\/2024"],"award-info":[{"award-number":["166\/UN3.LPPM\/PT.01.09\/2024"]}],"id":[{"id":"10.13039\/501100008463","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Hypertension is the leading noncommunicable disease case affecting 1.28 billion individuals worldwide, with most cases located in low- and middle-income countries. While there are numerous techniques for treating mild to moderate hypertension, properly controlling severe or resistant hypertension poses substantial challenges. Ultrasound-based renal denervation (uRDN) has emerged as a promising non-pharmacological approach. This study aims to investigate the safety and efficacy of uRDN in hypertensive patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The literature search across PubMed, ScienceDirect, BMJ Journals, ProQuest, and Springer databases yielded 419 articles. A total of 395 articles were filtered, leading to 24 articles assessed for eligibility and overall analysis, which resulted in eight included studies for quantitative synthesis. Quality appraisal used RoB 2.0, while meta-analysis used RevMan 5.4.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Our analysis results indicated significant improvements in 24-hour, daytime, and home ambulatory blood pressure measurements, favoring the uRDN over control. The mean difference (MD) for 24-hour measurements was -0.84 mmHg [95% CI -1.14, -0.55; p &lt; 0.00001], for daytime measurements -1.27 mmHg [95% CI -1.59, -0.95; p &lt; 0.00001], and for home measurements -1.98 mmHg [95% CI -2.32, -1.64; p &lt; 0.00001], with moderate heterogeneity observed. Office ambulatory measurements also favored the uRDN with a significant MD of -1.51 mmHg [95% CI -1.91; -1.10; p &lt; 0.00001]. Funnel plots revealed some outliers, indicating true heterogeneity among the studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>uRDN was associated with a significant reduction (-2.32 to -0.10 mmHg) in blood pressure of hypertensive patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0311191","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:40:27Z","timestamp":1736966427000},"page":"e0311191","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ultrasound renal denervation in hypertensive patients: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"20","author":[{"given":"Roy Novri","family":"Ramadhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5482-0613","authenticated-orcid":true,"given":"Derren David Christian Homenta","family":"Rampengan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5016-9592","authenticated-orcid":true,"given":"Felicia Angelica","family":"Gunawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Nathania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8039-0574","authenticated-orcid":true,"given":"Sebastian Emmanuel","family":"Willyanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5167-3147","authenticated-orcid":true,"given":"Hiroyuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mochammad","family":"Thaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satriyo Dwi","family":"Suryantoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6448-7642","authenticated-orcid":true,"given":"Maulana Antiyan","family":"Empitu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"pone.0311191.ref001","article-title":"Hypertension Fact Sheets.","journal-title":"WHO."},{"issue":"10226","key":"pone.0311191.ref002","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","article-title":"Modifiable risk factors, cardiovascular disease, and mortality in 155\u2008722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.","volume":"395","author":"S Yusuf","year":"2020","journal-title":"The Lancet"},{"issue":"10159","key":"pone.0311191.ref003","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"392","author":"JD Stanaway","journal-title":"The Lancet"},{"issue":"2","key":"pone.0311191.ref004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.17925\/HI.2019.13.2.12","article-title":"Renal Denervation in High-risk Patients with Hypertension.","volume":"13","author":"MJ Heradien","year":"2019","journal-title":"Heart Int"},{"issue":"3","key":"pone.0311191.ref005","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/HYPERTENSIONAHA.122.20373","article-title":"Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial","volume":"80","author":"CG Derington","year":"2023","journal-title":"Hypertension"},{"issue":"10","key":"pone.0311191.ref006","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/bcp.14033","article-title":"Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50","volume":"85","author":"SB Dimmitt","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"pone.0311191.ref007","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"PK Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"33","key":"pone.0311191.ref008","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"B Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"pone.0311191.ref009","article-title":"Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association","author":"NK Choudhry","year":"2022","journal-title":"Hypertension"},{"issue":"2","key":"pone.0311191.ref010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/HYPERTENSIONAHA.121.17102","article-title":"Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines","volume":"79","author":"BM Egan","year":"2022","journal-title":"Hypertension"},{"issue":"2","key":"pone.0311191.ref011","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41440-021-00754-7","article-title":"Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial.","volume":"45","author":"K Kario","year":"2022","journal-title":"Hypertension Research."},{"issue":"1","key":"pone.0311191.ref012","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1590\/2175-8239-jbn-2018-0213","article-title":"Renal sympathetic denervation for resistant hypertension: where do we stand after more than a decade.","volume":"42","author":"MAP Fontes","year":"2020","journal-title":"Silva ACS e.Brazilian Journal of Nephrology"},{"issue":"23","key":"pone.0311191.ref013","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jcin.2021.09.020","article-title":"Renal Denervation for Hypertension.","volume":"14","author":"Y Ahmad","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"10137","key":"pone.0311191.ref014","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.","volume":"391","author":"M Azizi","year":"2018","journal-title":"The Lancet"},{"key":"pone.0311191.ref015","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"pone.0311191.ref016","doi-asserted-by":"crossref","first-page":"e1024","DOI":"10.4244\/EIJ-D-21-00295","article-title":"Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial","volume":"17","author":"F Mahfoud","year":"2021","journal-title":"EuroIntervention"},{"issue":"5","key":"pone.0311191.ref017","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCULATIONAHA.118.037654","article-title":"A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN).","volume":"139","author":"K Fengler","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"pone.0311191.ref018","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/HJH.0000000000002092","article-title":"A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension","volume":"37","author":"M Azizi","year":"2019","journal-title":"J Hypertens"},{"issue":"10293","key":"pone.0311191.ref019","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.","volume":"397","author":"M Azizi","year":"2021","journal-title":"The Lancet"},{"issue":"8","key":"pone.0311191.ref020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027612","article-title":"Twenty\u2010Four\u2010Hour Blood Pressure\u2010Lowering Efficacy of Sacubitril\/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double\u2010Blind Multicenter Study.","volume":"12","author":"K Kario","year":"2023","journal-title":"J Am Heart Assoc."},{"issue":"7","key":"pone.0311191.ref021","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41371-021-00547-y","article-title":"Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study","volume":"36","author":"M Saxena","year":"2022","journal-title":"J Hum Hypertens"},{"issue":"8","key":"pone.0311191.ref022","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jama.2023.0713","article-title":"Endovascular Ultrasound Renal Denervation to Treat Hypertension","volume":"329","author":"M Azizi","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"pone.0311191.ref023","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1053\/j.ajkd.2022.03.015","article-title":"Renal Denervation: A Review","volume":"80","author":"J Rey-Garc\u00eda","year":"2022","journal-title":"American Journal of Kidney Diseases"},{"issue":"10108","key":"pone.0311191.ref024","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.","volume":"390","author":"RR Townsend","year":"2017","journal-title":"The Lancet"},{"issue":"9","key":"pone.0311191.ref025","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1097\/HJH.0000000000002120","article-title":"Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension","volume":"37","author":"J Daemen","year":"2019","journal-title":"J Hypertens"},{"issue":"10234","key":"pone.0311191.ref026","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.","volume":"395","author":"M B\u00f6hm","year":"2020","journal-title":"The Lancet"},{"issue":"10137","key":"pone.0311191.ref027","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"DE Kandzari","year":"2018","journal-title":"The Lancet"},{"issue":"5","key":"pone.0311191.ref028","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jamacardio.2023.0338","article-title":"Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials","volume":"8","author":"AJ Kirtane","year":"2023","journal-title":"JAMA Cardiol"},{"key":"pone.0311191.ref029","article-title":"Endovascular Ultrasound Renal Denervation for Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Sham-Controlled Trials","author":"N Felix","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"pone.0311191.ref030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/hr.2012.26","article-title":"Nocturnal blood pressure and cardiovascular disease: a review of recent advances.","volume":"35","author":"Y Yano","year":"2012","journal-title":"Hypertension Research"},{"key":"pone.0311191.ref031","article-title":"Can Antihypertensive Treatment Restore the Risk of Cardiovascular Disease to Ideal Levels","author":"K Liu","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"pone.0311191.ref032","article-title":"Guide to the methods of technology appraisal 2013 Process and methods [Internet].","author":"National Institute for Health and Care Excellence","year":"2013"},{"issue":"14","key":"pone.0311191.ref033","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jacc.2012.07.029","article-title":"Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension","volume":"60","author":"BP Geisler","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"pone.0311191.ref034","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40258-014-0116-7","article-title":"Cost Effectiveness of Renal Denervation Therapy for the Treatment of Resistant Hypertension in the UK.","volume":"12","author":"D Gladwell","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"issue":"9981","key":"pone.0311191.ref035","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","article-title":"Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.","volume":"385","author":"M Azizi","year":"2015","journal-title":"The Lancet"},{"key":"pone.0311191.ref036","article-title":"Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension.","author":"RS Taylor","year":"2024","journal-title":"Pharmacoecon Open"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:41:17Z","timestamp":1736966477000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311191"}},"subtitle":[],"editor":[{"given":"Vincenzo","family":"Lionetti","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311191","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]}}}